If you’re a Canadian with a TFSA 🇨🇦, did you know that your contribution room increases with your investments?
I once helped someone deposit $1M into their TFSA.
Tax-Free.
1
114
$HIMS: Stock Review as of 11/13/26
Hims & Hers reported Q3 revenue of $890.4M, up 49% year over year and 18% from Q2. US revenue grew 21%, and international revenue rose to $233.3M from $55.5M, helped by the Eucalyptus acquisition. Growth came from spending per customer, not customer count: monthly revenue per subscriber rose 30% to $105, while subscribers fell by 103K from Q2 to 2.79M. Profitability moved the other way. Gross margin dropped to 57.2% from 73.8% a year ago as weight-loss products and shorter shipping cycles raised costs, and no one-time charge sits behind that number. GAAP operating loss was $66.1M and net loss was $33.0M, or -$0.14 per share, against net income of $15.8M a year ago. Adjusted EBITDA was $82.4M, a 9.3% margin, up 5%.
Cash flow weakened. Operating cash flow fell to $65.4M from $148.7M, and that figure included $433.3M of proceeds from receivables sold to JPMorgan. Free cash flow fell 67% to $26.0M even with capex down 43% to $39.4M. That free cash flow figure excludes acquisition payments. Hims paid $130.3M of deferred Eucalyptus consideration in the quarter, and nine-month free cash flow after deferred and earn-out payments was about -$173M. Cash and short-term investments fell $128.8M to $712.2M. The balance sheet carries $1.4B of zero-coupon convertible notes due 2030 and 2032, $563M of deferred acquisition payments, $171M of earn-outs and a $114.8M working-capital deficit. There have been no buybacks in 2026, and the share count is up 3.1% since December.
At the $19.73 close, HIMS has a $4.6B market cap and a $5.3B enterprise value, or $6.0B including the deferred payments and earn-outs. On sales it looks cheap. EV/Sales of 1.9x and P/S of 1.6x are 34-36% and 46-51% below their 3- and 5-year averages. The discount narrows to about 20% on EV/gross profit (3.0x), because gross margin has fallen from 74-82% to 57%. Forward EV/EBITDA of 18.2x is 24% below its 3-year average. Trailing P/E is not meaningful given the loss, and on cash flow the stock is expensive: P/FCF of 144x is about 2.7 times its 3-year average of 53x. HIMS still trades at a premium to telehealth peers TDOC (0.7x EV/Sales), WW (0.6x) and LFMD (0.5x). Short interest is about 22% of shares outstanding.
The Street is cautious. Of the 15 analysts covering the stock, 12 rate it Hold, up from 11 in August and September. Price targets range from $23 to $40, with an average of $28.31, about 43% above the current price. Most targets were cut after the print and may still lag the 24% drop from the Nov 6 close. The company's own outlook explains the caution: Hims cut its FY26 Adjusted EBITDA guidance to $257-277M, with the midpoint down about 11%, and its Q4 revenue guidance midpoint of $885M sits below Q3's $890.4M.
Revenue growth is real, and the stock sits at or below the bottom of its own sales-multiple history. The discount looks earned. Gross margin is down 17 points, GAAP earnings are negative, subscribers shrank, and free cash flow is thin once acquisition payments are counted. The catalysts to watch are January weight-loss demand with Lilly's drugs now on the platform, the FTC motion-to-dismiss hearing in January, the CEO's 10b5-1 sale plan that opens December 15, and the 2027 outlook due with Q4 results.
Until gross margin finds a floor, HIMS is cheap on sales but not on earnings or cash flow.
1
3
372
If you’re a Canadian 🇨🇦 REMEMBER to do these 3 THINGS before year-end
Max out TFSA room (2026 Contribution is $7K)
Max out the FHSA if you haven’t already ($40K lifetime limit, $8K annually)
Max out your RRSP, although contributions can be made first 90 days of 2027 too
$NVDA earnings is on Tuesday Nov 17. Therefore, Wednesday morning will determine if the “bubble” pops or if we’re okay.
Will be an interesting earnings call.
4
3
730
Good morning fam! What’s on the Saturday slate for today?
I’ll go first:
- gym
- card show
- haircut
- gaming
- relaxing
3
6
524
Why do people hate on folks who just chill and invest in $VOO?
$META: Stock Review as of 11/13/26
Meta reported Q3 revenue of $64.6B, up 26% year over year and 6% from Q2. Both volume and pricing contributed: ad impressions rose 10% and average price per ad rose 14%. Profitability moved the other way. GAAP operating income fell 37% to $13.0B, and operating margin dropped to 20.1% from 40.1% a year ago. The largest factor was a $9.89B charge for the settlement with 52 state attorneys general. Excluding it, operating income was $22.9B, a 35.4% margin. Gross margin also slipped to 79.3% from 82.0% as infrastructure and depreciation costs rose. Diluted EPS was $3.83.
Cash flow is the central issue. Capex, including finance-lease principal, reached $34.9B in the quarter, up 80% year over year and equal to 54% of revenue. Free cash flow was -$2.12B. Full-year capex guidance is $135-145B. Debt at face value rose from $59B to $84B over the first nine months, and since quarter end Meta has added $15B of USD notes, €9B of euro notes, a $12.5B mandatory convertible preferred and a 46M-share forward equity sale. There have been no buybacks in 2026.
At the $641.69 close, META trades at 19.5x forward earnings. That is 12% below both its 3-year and 5-year averages, and below GOOGL (21.5x), MSFT (25.2x) and AMZN (26.9x). The discount is narrower on trailing numbers: LTM EV/EBITDA of 15.9x is roughly in line with its 3-year average. On cash flow the stock is expensive. P/FCF is about 57x, roughly double its historical average, and the FCF yield is 1.8% against 3.8-4.3% historically. Several items sit outside enterprise value, including a $25B New Mexico civil penalty under appeal and a planned ~$60B Class C at-the-market offering expected no earlier than Q1 2027. S&P revised its outlook on Meta to negative on October 30.
The Street remains constructive. Price targets range from $629.06 to $1,050, with an average of $850.10, about 32% above the current price. Of the 61 analysts covering the stock in November, roughly 57 rate it Buy or Strong Buy, about 4 rate it Hold, and none rate it Sell. Buy ratings have edged down from 47 in September to 45.
The core ad business is performing well, and the forward multiple sits below both its own history and its megacap peers. The discount looks earned. Free cash flow has turned negative, consensus estimates imply it stays negative through 2028, and Meta is funding its buildout increasingly with debt and equity while carrying significant legal exposure. The catalysts to watch are 2027 capex guidance on the Q4 call, the timing and pricing of the Class C offering, and the New Mexico appeal.
Until spending visibility improves, META looks fairly valued rather than cheap.
2
1
167
FAA ISSUES A GROUND STOP FOR ALL DEPARTING AIRCRAFT IN THE US.
THIS HAS ONLY HAPPENED 2X IN HISTORY.
9/11/2001 and 1/11/2023.
JENSEN. OUTLOOK. FAA.
WHAT IS GOING ON?
1
256
My parents immigrated to Canada with no proper education and financial literacy. While they’ve done good for themselves over the years through work they never really had a retirement plan.
Now that I’m older, I’ve realized I am the retirement plan.
A few weeks ago I set them up with investing accounts and we recently deployed excess cash into the market. Both for growth and capital preservation since they’ll retire in about 10-15 years.
If you’re the son/daughter of an immigrant, please make sure you’re doing whatever you can to help secure your parent’s future. After all, they helped cement yours with their blood, sweat, and tears.
1
74
Did you buy $NVDA as of recently? I’ll be honest I picked up another $3K worth around $160 levels.
Good or bad buy?
3
2
223
